Consolidated Financial Results for the Three Months Ended June 30, 2026
(Under Japanese GAAP)

August 13, 2026

Name of Listed Company: **Kaneka Corporation** Stock Exchange Listing: Tokyo
Code Number: 4118 URL https://www.kaneka.co.jp/en/
Representative: Kazuhiko Fujii, President, Representative Director
Contact Person: Atsuya Inoguchi, Head of Investors Relations Department Phone: +81-3-5574-8090
Scheduled date of dividend distribution: —
Preparation of supplementary material on financial results: Yes
Holding of financial results briefing: Yes (for securities analysts and institutional investors)

Note: Figures have been rounded down to the nearest million yen.

1. Consolidated Financial Results for the Three Months Ended June 30, 2026 (from April 1, 2026 to June 30, 2026)

(1) Consolidated operating results

(% indicates year-on-year change)

	Net sales		Operating income		Ordinary income		Net income attributable to owners of parent	
	¥ million	%	¥ million	%	¥ million	%	¥ million	%
Apr.1, 2026 – Jun. 30, 2026	223,025	12.3	14,944	83.1	13,750	127.7	8,941	109.8
Apr.1, 2025 – Jun. 30, 2025	198,682	0.2	8,161	(20.6)	6,038	(40.5)	4,261	(39.4)

Note: Comprehensive income: ¥11,129 million [143.7%] for the three months ended June 30, 2026
¥4,567 million [(70.9%)] for the three months ended June 30, 2025

	Basic net income per share	Diluted net income per share
	¥	¥
Apr.1, 2026 – Jun. 30, 2026	148.46	147.90
Apr.1, 2025 – Jun. 30, 2025	67.74	67.53

(2) Consolidated financial position

	Total assets	Net assets	Equity ratio
	¥ million	¥ million	%
As of June 30, 2026	983,013	527,734	51.3
As of March 31, 2026	959,154	521,669	52.0

Reference: Equity (Shareholders' equity + Accumulated other comprehensive income):
¥504,193 million as of June 30, 2026
¥498,656 million as of March 31, 2026

2. Dividends

	Annual dividends				
	1st Quarter	2nd Quarter	3rd Quarter	Year-end	Annual
	¥	¥	¥	¥	¥
Apr.1, 2025 – Mar. 31, 2026	—	80.00	—	80.00	160.00
Apr.1, 2026 – Mar. 31, 2027	—				
Apr.1, 2026 – Mar. 31, 2027 (Forecasts)		105.00	—	105.00	210.00

Note: Changes in dividend forecast during the quarter under review: None

3. Forecast for Consolidated Financial Results for the Fiscal Year Ending March 31, 2027 (from April 1, 2026 to March 31, 2027)

(Percentage figures represent changes from the corresponding periods of the previous fiscal year)

	Net sales		Operating income		Ordinary income		Net income attributable to owners of parent		Net income per share
	¥ million	%	¥ million	%	¥ million	%	¥ million	%	¥
Full year	820,000	1.0	36,000	9.4	32,000	10.8	31,500	1.7	523.04

Note: Revisions to consolidated business performance forecasts during the quarter under review: None

* Notes

(1) Changes in the scope of consolidation during the term: Yes
Newly included: 1 company (Company name) Kaneka Korea Corporation
Excluded: 1 company (Company name) AB BIOTICS PTE.LTD.

(2) Application of simplified methods of accounting and specific accounting methods: None

(3) Changes in accounting principles, changes in estimates, or restatements
1. Changes owing to revisions in accounting standards: None
2. Changes other than 1. above: None
3. Changes in accounting estimates: None
4. Restatements: None

(4) Number of shares issued (common stock)

1. Number of shares issued at the end of the period (including treasury stock):	June 30, 2026	63,000,000 shares	March 31, 2026	63,000,000 shares
2. Number of shares of treasury stock at the end of the period:	June 30, 2026	2,857,530 shares	March 31, 2026	2,774,693 shares
3. Average number of shares outstanding during the period (calculated cumulatively from the beginning of the fiscal year):	June 30, 2026	60,227,163 shares	June 30, 2025	62,909,810 shares

* Review of the accompanying quarterly consolidated financial statements by certified public accountants or an audit firm：None

* Explanations or other items pertaining to appropriate use of business performance forecasts.
The business performance forecasts, and certain other statements contained in this document are forward-looking statements, which are based on information currently available to the Company and certain assumptions determined to be reasonable by the Company. For a variety of reasons, actual performance may differ substantially from these forecasts. They do not constitute a guarantee that the Company will achieve these forecasts or other forward-looking statements. For cautionary items used in business performance forecasts, please refer to the section entitled “(3) Earnings Forecasts and Other Forward-looking Statements” under “1. Quarterly Consolidated Financial Results” on page 4.

Supplementary Materials

Contents

1. Quarterly Consolidated Financial Results---------- P. 2
(1) Operating Results ---------- P. 2
(2) Financial Position ---------- P. 4
(3) Earnings Forecasts and Other Forward-looking Statements ---------- P. 4
2. Quarterly Consolidated Financial Statements and Main Notes ---------- P. 5
(1) Quarterly Consolidated Balance Sheets ---------- P. 5
(2) Quarterly Consolidated Statements of Income and Comprehensive Income ---------- P. 7
(3) Notes to the Consolidated Financial Statements ---------- P. 9
(Segment Information) ---------- P. 9
(Notes in the Event of Significant Changes in the Amount of Shareholders' Equity) --- P. 11
(Going Concern Assumption) ---------- P. 11
(Notes on Quarterly Consolidated Statements of Cash Flows) ---------- P. 11

1. Quarterly Consolidated Financial Results

(1) Operating Results

➢ State of Global Economy – Concerns over an economic downturn persist -

As military tensions remain unresolved, the global economy's turmoil continues.
Inflation concerns are rising in Europe and the U.S. China faces a delay in the recovery of domestic demand while Japan is concerned that rising prices driven by a weak yen could weigh on the economy.
Concerns over an economic downturn persist as there is no clear path toward stabilizing the situation in the Middle East.

➢ Kaneka Group's Business Performance – Sales and profits increased –

Under these circumstances, Kaneka Group's business performance for the first three months (April 1, 2026 to June 30, 2026, "1Q") was as follows. Consolidated net sales were ¥223,025 million (up 12.3% year-on-year), operating income was ¥14,944 million (up 83.1% year-on-year), ordinary income was ¥13,750 million (up 127.7% year-on-year), and net income attributable to owners of parent was ¥8,941 million (up 109.8% year-on-year).
Net sales, operating income, ordinary income, and net income attributable to owners of parent all significantly exceeded the figures for the same period last year.

Business performance for the first three months (April 1, 2026 to June 30, 2026) (Millions of yen)

	FY2025 1Q(Apr.-Jun.)	**FY2026 1Q(Apr.-Jun.)**	Difference (year-on-year)
Net sales	198,682	**223,025**	24,342 12.3%
Operating income	8,161	**14,944**	6,783 83.1%
Ordinary income	6,038	**13,750**	7,711 127.7%
Net income attributable to owners of parent	4,261	**8,941**	4,679 109.8%

Net sales and operating income by business segment (Millions of yen)

	Net sales			**Operating income**		
	FY2025 1Q(Apr.-Jun.)	**FY2026 1Q(Apr.-Jun.)**	Difference (year-on-year)	FY2025 1Q(Apr.-Jun.)	**FY2026 1Q(Apr.-Jun.)**	Difference (year-on-year)
Material SU	82,374	**94,444**	12,069 14.7%	6,265	**10,858**	4,592 73.3%
Quality of Life SU	48,466	**53,849**	5,382 11.1%	5,208	**7,006**	1,797 34.5%
Health Care SU	18,273	**22,026**	3,753 20.5%	3,131	**3,486**	354 11.3%
Nutrition SU	49,310	**52,434**	3,123 6.3%	2,680	**3,363**	682 25.5%
Others	257	**270**	13 5.1%	128	**140**	11 9.1%
Adjustment	-	**-**	-	(9,254)	**(9,910)**	(655) -
Total	198,682	**223,025**	24,342 12.3%	8,161	**14,944**	6,783 83.1%

* SU: Solutions Unit

➢ Remarks on the Group-wide Business Performance

In 1Q, we responded swiftly to an uncertain business environment, including petrochemical supply chain disruptions triggered by heightened tensions in the Middle East and evolving economic conditions across global markets, thereby gaining strong market trust. We implemented agile price revisions in response to soaring prices of raw materials.

Our greatest mission is to continuously provide the market with a stable supply of differentiated products. Leveraging raw materials procurement capabilities and product supply network, including logistics, we appropriately implemented product price adjustments.

Furthermore, sales in the Health Care Solutions Unit and Supplemental Nutrition continue to increase. We are steadily moving toward our target portfolio. As a result, all units recorded increased sales and profits in 1Q, surpassing the business performance in 4Q of the previous fiscal year (January 1, 2026 to March 31, 2026). Growth momentum continues to accelerate.

The operating performance by business segment was as follows:

(i) Material Solutions Unit

This unit recorded increased sales and profits as a whole by implementing price revisions.

- For Vinyls and Chlor-Alkali, by ensuring a stable supply, we successfully implemented price revisions to reflect rising costs, resulting in increased sales and profits.
- For Modifiers, sales remained strong at all global bases. By meeting customer demand for differentiated products, we ensured a stable supply, which led to price revisions and increase in sales and profits. Sales of MX, a high-value-added product, have further expanded.
- For Modified Silicone polymers, sales volume increased as the replacement of other materials progressed. Sales and profit also increased as a result of efforts to prioritize a stable supply of products with unique functional properties and revise product prices in response to soaring raw material costs.
- For Green Planet®, societal implementation is steadily progressing with new applications such as the adoption for the use in artificial turf. The further expansion of its adoption such as cutlery and packaging materials is expected both domestically and internationally through continued collaboration with global brand holders.

(ii) Quality of Life Solutions Unit

This unit posted increased sales and profits as a whole.

- For Foam & Residential Techs, sales increased in the agricultural, fishery, and construction sectors by ensuring a stable supply amid tight market supply conditions. In addition, profit margins improved mainly due to cost reductions and product price revisions enabled by continued stable supply.
- For E & I Technology, sales of optical films for large-screen LCD TVs remained strong. Despite polyimide films being impacted by production adjustments in the smartphone market, overall sales and profits increased.
- For PV & Energy management, sales of high-efficiency photovoltaic modules for domestic single homes remained firm. Development of mass production technology for tandem-type perovskite photovoltaic modules is proceeding in a planned manner.
- For Performance Fibers, sales of hair attachment products and flame-retardant fabrics remained strong. We will further expand markets by broadening the product lineup.

(iii) Health Care Solutions Unit

This unit reported increased sales and profits as a whole, driven by strong growth in Medical.

- For Medical, sales of both blood purification devices and catheters expanded, leading to a substantial increase in profit. Overseas sales expansion also progressed, and the effects of M&A (EndoStream Medical Ltd. and Zeon Medical Inc.'s business) are beginning to contribute to results.

- For Pharma, partly due to the concentration of sales in 4Q of the previous fiscal year, shipments declined. We are working to acquire new projects by strengthening development capabilities in small molecule pharmaceuticals and biopharmaceuticals.

(iv) Nutrition Solutions Unit

This unit saw increased sales and profits due to momentum from both strong sales of Supplemental Nutrition and improved profitability in Foods & Agris.

- For Supplemental Nutrition, sales of the active form of coenzyme Q10 increased, primarily in the U.S. and Asia. Sales of probiotics are also growing steadily.
- For Foods & Agris, the shift toward high-value-added products progressed, alongside price revisions. We will further increase sales of “Business to Consumer” products.

(2) Financial Position for the First Three Months Ended June 30, 2026

As of June 30, 2026, total assets were ¥983,013 million, up ¥23,858 million from the previous fiscal year-end. This is mainly due to an increase in inventories and property, plant and equipment.
Liabilities totaled ¥455,278 million, up ¥17,793 million, primarily due to an increase in trade payables and loans payable.
Net assets were ¥527,734 million, up ¥6,064 million, owing chiefly to an increase in retained earnings, which offset dividend payments and an increase in treasury shares. Equity ratio was 51.3%.

(3) Earnings Forecasts and Other Forward-looking Statements

We anticipate that the business environment will remain unpredictable and continue to be highly volatile into and beyond 2Q (July 1, 2026 to September 30, 2026). With cost increases expected to continue in certain product categories, we will continue to work to secure profit margins.

In Health Care Solutions Unit, our priority area, we expect to expand sales of new Medical products and broaden our sales areas, as well as acquire more new projects for small molecule pharmaceuticals and biopharmaceuticals in Pharma.

In Quality of Life Solutions Unit, continued sales growth is expected for high-value-added grades (such as high-frequency PI and modified optical acrylic resins) in E & I Technology, and demand for Performance Fibers is also expected to remain robust.

In Nutrition Solutions Unit, sales of the active form of coenzyme Q10 are expected to increase in Supplemental Nutrition, primarily in the U.S. and Asia, while Foods & Agris is projected to see improved profitability through expanded sales of high-value-added products and price revisions.

In Material Solutions Unit, for Vinyls and Chlor-Alkali, we will work to stabilize profit margins, while for Modifiers, we will increase sales of high-value-added products such as non-PVC and MX, and for Modified Silicone polymers, we will promote sales increase through its collaboration with Cemedine Co., Ltd.

Considering the above, we have not revised the forecast for consolidated financial results announced on May 14, 2026.
We will promptly revise and disclose earnings forecasts as soon as it becomes reasonably predictable.

2. Quarterly Consolidated Financial Statements and Main Notes

(1) Quarterly Consolidated Balance Sheets

(Millions of yen)

	FY2025 As of March 31, 2026	FY2026 1st Quarter As of June 30, 2026
Assets		
Current assets		
Cash and deposits	50,973	52,576
Notes and accounts receivable-trade, and contract assets	163,638	162,756
Electronically recorded monetary claims	18,730	20,348
Merchandise and finished goods	110,765	117,616
Work in process	17,396	17,783
Raw materials and supplies	75,634	82,931
Other	30,465	32,212
Allowance for doubtful accounts	(1,885)	(1,910)
Total current assets	465,718	484,314
Noncurrent assets		
Property, plant and equipment		
Buildings and structures, net	108,601	108,188
Machinery, equipment and vehicles, net	125,864	127,264
Other, net	121,314	124,543
Total property, plant and equipment	355,780	359,996
Intangible assets		
Goodwill	2,213	2,146
Other	30,949	31,058
Total intangible assets	33,163	33,204
Investments and other assets		
Investment securities	52,139	52,649
Retirement benefit assets	34,035	34,206
Other	18,699	19,018
Allowance for doubtful accounts	(382)	(375)
Total investments and other assets	104,492	105,498
Total noncurrent assets	493,436	498,698
Total assets	959,154	983,013

(Millions of yen)

	FY2025 As of March 31, 2026	FY2026 1st Quarter As of June 30, 2026
Liabilities		
Current liabilities		
Notes and accounts payable-trade	81,006	88,001
Electronically recorded obligations-operating	5,245	5,625
Short-term loans payable	139,531	153,469
Income taxes payable	9,480	4,402
Provision	2,117	1,214
Other	66,673	69,782
Total current liabilities	304,056	322,496
Noncurrent liabilities		
Bonds payable	15,000	15,000
Long-term loans payable	59,045	58,592
Provision	861	793
Retirement benefit liabilities	20,076	19,915
Other	38,445	38,481
Total noncurrent liabilities	133,429	132,782
Total liabilities	437,485	455,278
Net assets		
Shareholders' equity		
Capital stock	33,046	33,046
Capital surplus	30,084	30,091
Retained earnings	359,255	363,639
Treasury stock	(11,400)	(11,865)
Total shareholders' equity	410,986	414,912
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	23,556	23,905
Foreign currency translation adjustment	37,225	39,266
Remeasurements of defined benefit plans	26,887	26,107
Total accumulated other comprehensive income	87,669	89,280
Subscription rights to shares	770	757
Non-controlling interests	22,241	22,783
Total net assets	521,669	527,734
Total liabilities and net assets	959,154	983,013

(2) Quarterly Consolidated Statements of Income and Comprehensive Income

Quarterly Consolidated Statements of Income (Millions of yen)

	FY2025 1st Quarter Three months ended June 30, 2025	FY2026 1st Quarter Three months ended June 30, 2026
Net sales	198,682	223,025
Cost of sales	144,469	157,446
Gross profit	54,213	65,579
Selling, general and administrative expenses	46,052	50,635
Operating income	8,161	14,944
Non-operating income		
Dividends income	832	675
Foreign exchange gains	–	336
Equity in earnings of affiliates	13	54
Other	417	323
Total non-operating income	1,263	1,390
Non-operating expenses		
Interest expenses	1,013	1,094
Loss on retirement of noncurrent assets	723	943
Foreign exchange losses	1,136	–
Other	513	545
Total non-operating expenses	3,386	2,584
Ordinary income	6,038	13,750
Extraordinary income		
Gain on sales of investment securities	1,075	–
Total extraordinary income	1,075	–
Extraordinary losses		
Patent protection court costs	261	330
Total extraordinary losses	261	330
Income before income taxes	6,852	13,419
Income taxes-current	2,550	4,161
Income taxes-deferred	(294)	(237)
Total income taxes	2,255	3,923
Net income	4,596	9,496
Net income attributable to non-controlling interests	335	555
Net income attributable to owners of parent	4,261	8,941

Quarterly Consolidated Statements of Comprehensive Income

(Millions of yen)

	FY2025 1st Quarter Three months ended June 30, 2025	FY2026 1st Quarter Three months ended June 30, 2026
Net income	4,596	9,496
Other comprehensive income		
Valuation difference on available-for-sale securities	(396)	342
Foreign currency translation adjustment	536	2,071
Remeasurements of defined benefit plans, net of tax	(170)	(779)
Share of other comprehensive income of associates accounted for using equity method	0	(0)
Total other comprehensive income	(29)	1,633
Comprehensive income	4,567	11,129
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	4,027	10,551
Comprehensive income attributable to non-controlling interests	540	578

(3) Notes to the Consolidated Financial Statements
(Segment Information)

I For the three months ended June 30, 2025
1) Sales and Income by Segment

(Millions of yen)

	Reportable Segment					Others (Note 1)	Total	Adjustment	Amounts on consolidated financial statements (Note 2)
	Material Solutions Unit	Quality of Life Solutions Unit	Health Care Solutions Unit	Nutrition Solutions Unit	Total				
Sales									
Customers	82,374	48,466	18,273	49,310	198,425	257	198,682	–	198,682
Intersegment	66	18	19	17	122	367	489	(489)	–
Total	82,440	48,484	18,292	49,328	198,547	625	199,172	(489)	198,682
Segment profit	6,265	5,208	3,131	2,680	17,287	128	17,415	(9,254)	8,161

Notes: 1. “Others” is a business segment that is not included in the reportable segments and includes property insurance and life insurance business.
2. Segment profit is reconciled with operating income in the quarterly consolidated financial statements.

2) Reconciliation between Segment Totals and Amounts on Quarterly Consolidated Financial Statements (Adjustments)

(Millions of yen)

Income	Amount
Segment total	17,287
Segment profit of Others	128
Elimination of intersegment transactions	0
Corporate expenses (Note)	(9,260)
Other adjustments	6
Operating income in the quarterly consolidated statements of income	8,161

Note: Corporate expenses primarily are expenses for basic R&D that are not allocable to any reportable segments.

Ⅱ For the three months ended June 30, 2026

1) Sales and Income by Segment

(Millions of yen)

	Reportable Segment					Others (Note 1)	Total	Adjustment	Amounts on consolidated financial statements (Note 2)
	Material Solutions Unit	Quality of Life Solutions Unit	Health Care Solutions Unit	Nutrition Solutions Unit	Total				
Sales									
Customers	94,444	53,849	22,026	52,434	222,754	270	223,025	–	223,025
Intersegment	102	29	-	18	150	370	520	(520)	–
Total	94,546	53,879	22,026	52,452	222,905	640	223,546	(520)	223,025
Segment profit	10,858	7,006	3,486	3,363	24,714	140	24,855	(9,910)	14,944

Notes: 1. “Others” is a business segment that is not included in the reportable segments and includes property insurance and life insurance business.
2. Segment profit is reconciled with operating income in the quarterly consolidated financial statements.

2) Reconciliation between Segment Totals and Amounts on Quarterly Consolidated Financial Statements (Adjustments)

(Millions of yen)

Income	Amount
Segment total	24,714
Segment profit of Others	140
Elimination of intersegment transactions	-
Corporate expenses (Note)	(9,910)
Other adjustments	(0)
Operating income in the quarterly consolidated statements of income	14,944

Note: Corporate expenses primarily are expenses for basic R&D that are not allocable to any reportable segments.

(Notes in the Event of Significant Changes in the Amount of Shareholders' Equity)
Not applicable

(Going Concern Assumption)
Not applicable

(Notes on Quarterly Consolidated Statements of Cash Flows)
The quarterly consolidated statement of cash flows for the three months ended June 30, 2026 has not been prepared. Depreciation (including amortization of intangible assets other than goodwill) and amortization of goodwill for the three months ended June 30, 2025 and June 30, 2026 is as follows:

(Millions of yen)

	FY2025 1st Quarter Three months ended June 30, 2025	FY2026 1st Quarter Three months ended June 30, 2026
Depreciation	11,532	12,064
Amortization of Goodwill	202	105

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.